Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart home monitoring could help pancreatic cancer patients avoid hospital stays

NCT ID NCT04263948

Symptom relief Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tested a home monitoring system for people with advanced pancreatic cancer receiving a strong chemotherapy called mFOLFIRINOX. The system tracked symptoms, activity, sleep, and weight using connected devices and an online platform. The goal was to see if early alerts could help doctors respond quickly to side effects and reduce emergency hospital visits. The study involved 58 patients in France over 7 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PiCaDo telemonitoring system (device and internet platform)
What this could lead to
If successful, this could help doctors detect problems earlier in pancreatic cancer patients on chemotherapy, potentially reducing emergency hospital visits and improving quality of life.
What could go wrong
This is a small, completed study with only 58 participants, so results may not apply to all patients. The monitoring system itself does not treat the cancer, and technical issues or patient non-use could limit its effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

58 people

The number who actually took part.

Started

Jun 2021

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: -Histological or cytological diagnosis of pancreatic adenocarcinoma * Locally advanced or metastatic pancreatic cancer * With or without previous surgery (pancreas and / or metastases) * Performance status of 0 or 1 according to WHO * Age between 18 and 85 years old included * No history of prior chemotherapy or radiotherapy * Absence of cutaneous or mucosal jaundice or skin pruritus * No proven thrombosis * Absence of heart disease or other pathology poorly controlled by current treatments * Bilirubinemia and alkaline phosphatases \<1.5 ULN (with or without stent) * Hematological, renal and hepatic laboratory tests authorizing the administration of mFOLFIRINOX * Affiliated subject or beneficiary of a social security scheme * Patient who freely signed informed consent Exclusion Criteria: * Immediately resectable pancreatic cancer * No histological or cytological evidence of pancreatic adenocarcinoma * Performance status\> 1 (WHO) * Age \<18 and\> 85 years old * Prior administration of chemotherapy or radiotherapy * Skin jaundice and / or pruritus * Uncontrolled venous or arterial thrombosis * Co morbidity not controlled by a specific treatment * Biological anomalies contraindicating the administration of one or more drugs which make up FOLFIRINOX * Lack of GPRS coverage in the home * Patient participating in another clinical study * Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision * Pregnant, lactating or parturient woman * Patient hospitalized without consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreas cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm Motor Activity Neoplasm Metastasis pancreatic adenocarcinoma pancreatic neoplasm Patient Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreas cancer

Contacts and locations

Locations

  • Clinique du Mousseau

    Évry, IDF, 91000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.